An open-label, multicenter extension study of pertuzumab (rhuMAb 2C4) in subjects treated with pertuzumab in a previous Genentech-sponsored phase II cancer study
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2015
At a glance
- Drugs Pertuzumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Genentech
- 01 Jan 2008 Status change from in progress to completed.
- 02 Oct 2005 New trial record.